Drug intelligence / Profile preview

LAE112

Development stage: Preclinical
Lead developer: Laekna
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

LAE112 is a preclinical-stage monoclonal antibody developed by Laekna Therapeutics that targets Fibroblast Growth Factor Receptor 2b (FGFR2b). It is being investigated for the treatment of various cancers. As an internally discovered candidate, LAE112 is currently in the early discovery and proof-of-mechanism stages. FGFR2b is a splice variant of FGFR2 that is frequently overexpressed in epithelial-derived tumors, such as gastric and breast cancers, making it a specific target for therapeutic intervention. Laekna Therapeutics holds global commercial rights to this drug candidate.

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on LAE112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAE112.